HK1071567A1 - Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for thetreatment of obesity - Google Patents

Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for thetreatment of obesity

Info

Publication number
HK1071567A1
HK1071567A1 HK05104387A HK05104387A HK1071567A1 HK 1071567 A1 HK1071567 A1 HK 1071567A1 HK 05104387 A HK05104387 A HK 05104387A HK 05104387 A HK05104387 A HK 05104387A HK 1071567 A1 HK1071567 A1 HK 1071567A1
Authority
HK
Hong Kong
Prior art keywords
spirosubstituted
thetreatment
piperidines
obesity
receptor antagonists
Prior art date
Application number
HK05104387A
Other languages
English (en)
Inventor
Duane A Burnett
Wen-Lina Wu
Thavalakulam K Sasikumar
Martin S Domalski
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HK1071567A1 publication Critical patent/HK1071567A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK05104387A 2002-06-27 2005-05-25 Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for thetreatment of obesity HK1071567A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39181302P 2002-06-27 2002-06-27
PCT/US2003/020088 WO2004002987A1 (en) 2002-06-27 2003-06-26 Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity

Publications (1)

Publication Number Publication Date
HK1071567A1 true HK1071567A1 (en) 2005-07-22

Family

ID=30000757

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05104387A HK1071567A1 (en) 2002-06-27 2005-05-25 Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for thetreatment of obesity

Country Status (15)

Country Link
US (1) US7109207B2 (xx)
EP (1) EP1532147B1 (xx)
JP (1) JP4522853B2 (xx)
CN (1) CN100374440C (xx)
AR (1) AR040344A1 (xx)
AT (1) ATE334983T1 (xx)
AU (1) AU2003258957A1 (xx)
CA (1) CA2490531C (xx)
DE (1) DE60307289T2 (xx)
ES (1) ES2266861T3 (xx)
HK (1) HK1071567A1 (xx)
MX (1) MXPA05000185A (xx)
PE (1) PE20040749A1 (xx)
TW (1) TW200401777A (xx)
WO (1) WO2004002987A1 (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7084156B2 (en) 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
EP1595867A4 (en) 2003-02-10 2008-05-21 Banyu Pharma Co Ltd PIPERIDINE DERIVATIVES AS AN ACTIVE ANTAGONIST AT THE RECIPE OF MELANIN CONCENTRATING HORMONE
JP4570165B2 (ja) * 2003-02-28 2010-10-27 シェーリング コーポレイション 肥満および関連障害の処置のための選択的ｍｃｈレセプターアンタゴニストとしてのビアリールテトラヒドロイソキノリンピペリジン
WO2005092858A2 (en) 2004-03-29 2005-10-06 Pfizer Japan Inc. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
CA2602716A1 (en) * 2005-03-29 2006-10-05 Banyu Pharmaceutical Co., Ltd. Therapeutic agent for non-alcoholic fatty liver disease, and screening method for drug candidate compound for treatment or prevention of non-alcoholic fatty liver disease
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118853A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2007118854A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
JPWO2008038692A1 (ja) * 2006-09-28 2010-01-28 萬有製薬株式会社 ジアリールケチミン誘導体
WO2008124118A1 (en) * 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
WO2011146069A1 (en) 2010-05-21 2011-11-24 Hewlett-Packard Development Company, L.P. Fluid ejection device including recirculation system
US9963739B2 (en) 2010-05-21 2018-05-08 Hewlett-Packard Development Company, L.P. Polymerase chain reaction systems
EP3221314B1 (en) * 2014-11-21 2019-07-03 Esteve Pharmaceuticals, S.A. Spiro-isoquinoline-1,4'-piperidine compounds having multimodal activity against pain
CN107312056B (zh) * 2017-08-24 2019-10-25 广西师范学院 2-(3’-羟基-17’-孕甾烷基)-5-氟苯并咪唑的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908830A (en) 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
CA2381111A1 (en) 1999-08-26 2001-03-01 Leah M. Giupponi Npy antagonists: spiroisoquinolinone derivatives
AU4928101A (en) * 2000-03-23 2001-10-03 Merck & Co Inc Spiropiperidine derivatives as melanocortin receptor agonists
AU783403B2 (en) 2000-07-05 2005-10-20 H. Lundbeck A/S Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof

Also Published As

Publication number Publication date
EP1532147A1 (en) 2005-05-25
US20040024002A1 (en) 2004-02-05
WO2004002987A1 (en) 2004-01-08
US7109207B2 (en) 2006-09-19
EP1532147B1 (en) 2006-08-02
PE20040749A1 (es) 2004-10-23
CN1665812A (zh) 2005-09-07
TW200401777A (en) 2004-02-01
AR040344A1 (es) 2005-03-30
ES2266861T3 (es) 2007-03-01
DE60307289T2 (de) 2007-10-18
CA2490531A1 (en) 2004-01-08
ATE334983T1 (de) 2006-08-15
CN100374440C (zh) 2008-03-12
MXPA05000185A (es) 2005-04-08
JP4522853B2 (ja) 2010-08-11
AU2003258957A1 (en) 2004-01-19
CA2490531C (en) 2011-03-22
JP2005535641A (ja) 2005-11-24
DE60307289D1 (de) 2006-09-14

Similar Documents

Publication Publication Date Title
HK1071567A1 (en) Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for thetreatment of obesity
AU2003243497A8 (en) Antagonists of melanin concentrating hormone receptor
EP1653960A4 (en) MELANIN CONCENTRATION HORMONE RECEPTOR ANTAGONIST
IL190898A0 (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
AU2003261392A8 (en) M3muscarinic acetylcholine receptor antagonists
IL175025A0 (en) Therapeutic regimens for baff antagonists
AU2003287880A8 (en) Cyclic quinoline compounds for use in mch receptor related disorders
EP1444251A4 (en) CYCLIC PEPTIDES AS G PROTEIN-COUPLED RECEPTOR ANTAGONISTS
HK1107261A1 (en) Method of wound healing using a2b adenosine receptor antagonists
EP1536813A4 (en) COMPOSITIONS AND METHODS FOR PROTEIN-ACTIVATED RECEPTOR ANTAGONISTS
AU2003267088A1 (en) Chemokine receptor antagonists as therapeutic agents
AU2003300904A8 (en) Antagonists for human prolactin
AU2003243654A8 (en) Internal support apparatus for downhole tubular structures
IL180098A0 (en) Methods for predicting therapeutic pesponse to agents acting on the growth hormone receptor
HK1082796A1 (zh) 人p2y15g蛋白偶聯受體的調控
IL180107A0 (en) Lactam tachykinin receptor antagonists
HK1085926A1 (en) Use of bradykinin-b2 receptor antagonists for treating osteoarthrosis
AU2003297124A8 (en) F11 receptor(f11r) antagonists as therapeutic agents
AU2003250685A8 (en) Methods of identifying selective beta-1-adrenergic receptor antagonists
ZA200602499B (en) Melanin concentrating hormone antagonists
AU2003242848A8 (en) Nuclear hormone receptor ligano-binding domain containing protein
TW535558U (en) Improved structure of device for clamping toilet device
AU2003244831A8 (en) Human nuclear hormone receptor
AU2002320824A1 (en) Regulation of human trace amine receptor ta5
SI1594520T1 (sl) Uporaba antagonistov bradikinin-B2 receptorja za zdravljenje osteoartroze

Legal Events

Date Code Title Description
CORR Corrigendum

Free format text: CORRECTED DATA OF SECTION 20 TO JOURNAL OF 20050722: [54] SPIROSUBSTITUTED PIPERIDINES AS SELECTIVEMELANIN CONCENTRATING - HORMONE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100626